The ongoing spread of H5N1 avian influenza in wild birds, poultry, and now cattle in the U.S. has raised concerns about the potential for this dangerous virus to spread efficiently between people, which could trigger an influenza pandemic. While there are no signs of this happening yet, it's important to understand our vaccine preparedness in case the situation changes. The good news is that existing systems and prior research would enable scientists to develop and manufacture an H5N1 vaccine relatively quickly, compared to the unprecedented timeline required for COVID-19 vaccines.
Vaccine Research and Development
Scientists have been studying H5N1 avian influenza viruses for decades, and have already developed candidate vaccine viruses (CVVs) that could be used to rapidly produce a well-matched vaccine if needed[4][7][13]. The CDC has confirmed that two of these existing H5N1 CVVs would likely provide good protection against the H5N1 strain currently spreading in U.S. birds and mammals[16]. Animal studies to further evaluate these vaccines are already underway[16].
Compared to COVID-19, the 70-year-old influenza vaccine research and production system would enable a much faster development timeline for an H5N1 vaccine[10]. It took about 1 week to produce mRNA and DNA flu vaccine candidates, 3 weeks for viral vector vaccines, and 2 months for protein-based flu vaccines[4] - significantly faster than the 10-15 years typically required for a new vaccine[8]. Clinical trials could also proceed rapidly, by simultaneously conducting different trial phases[8].
Vaccine Manufacturing
The U.S. already has a small H5N1 vaccine stockpile that could be used immediately if needed, with about 10 million bulk doses and hundreds of thousands of filled doses ready to go[15]. Large-scale production of additional doses could begin as soon as the CVVs complete initial safety testing[15].
However, the current global flu vaccine production capacity of about 5 billion doses per year is not sufficient to quickly immunize the world's population against a pandemic flu strain[11]. Scaling up manufacturing to produce the estimated 15 billion doses needed would be challenging, and strain the supply of raw materials like chicken eggs[3][11]. Manufacturers may also need to shift production away from seasonal flu vaccines[10].
Newer vaccine production technologies like mRNA may help boost capacity and speed. But most flu vaccines are still produced using the time-consuming egg-based process, taking about 6 months per batch[15]. Expanding global fill-and-finish capacity to place the bulk vaccine into vials will also be critical[4].
Vaccine Distribution
Distributing billions of H5N1 vaccine doses worldwide would be a monumental challenge, requiring careful planning of transportation and cold-chain logistics, facilities, and workforce[3][11][19]. Existing flu vaccine distribution channels would need to scale up by about 4-fold in capacity[3]. An estimated 200,000 pallet shipments, 15 million cooling boxes, and 15,000 flights would be required for global distribution[11].
The U.S. has a well-developed system for distributing flu vaccines domestically through public health departments, healthcare facilities, and pharmacies[14]. But many countries lack sufficient cold chain infrastructure to receive and disseminate the vaccines locally[12]. Equitable global access to H5N1 vaccines will depend on international cooperation and coordination through programs like the WHO's Global Influenza Surveillance and Response System[10].
In summary, while the world is not fully prepared to produce and distribute H5N1 or other pandemic flu vaccines on a global scale, the scientific knowledge, technologies, and systems exist to mount a much faster response than was possible for COVID-19. With sustained investments in research, production capacity, and distribution infrastructure, our collective vaccine preparedness will continue to improve. In the meantime, careful monitoring of the evolving H5N1 situation and rapid vaccine development and deployment if needed will be critical to saving lives and minimizing global health impacts.
Citations:
[1] https://www.ncbi.nlm.nih.gov/books/NBK580009/
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6101019/
[3] https://www.capstonelogistics.com/blog/logistics-update-challenges-in-covid-19-vaccine-distribution/
[4] https://www.ncbi.nlm.nih.gov/books/NBK578854/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941393/
[6] https://www.who.int/teams/immunization-vaccines-and-biologicals/essential-programme-on-immunization/supply-chain
[7] https://www.cdc.gov/flu/avianflu/prevention.htm
[8] https://historyofvaccines.org/vaccines-101/how-are-vaccines-made/vaccine-development-testing-and-regulation/
[9] https://assets.kpmg.com/content/dam/kpmg/xx/pdf/2020/12/five-ways-to-optimize-the-covid-19-vaccine-supply-chain.pdf
[10] https://www.bbc.com/future/article/20240515-how-a-human-bird-flu-vaccine-could-protect-against-avian-influenza
[11] https://www.dhl.com/global-en/delivered/globalization/vaccine-distribution.html
[12] https://www.ncbi.nlm.nih.gov/books/NBK578023/
[13] https://www.cdc.gov/flu/avianflu/hpai/hpai-interim-recommendations.html
[14] https://www.pfizer.com/science/coronavirus/vaccine/manufacturing-and-distribution
[15] https://www.statnews.com/2024/04/24/h5n1-bird-flu-vaccine-preparedness/
[16] https://www.cdc.gov/flu/avianflu/spotlights/2023-2024/avian-situation-update-05032024.htm
[17] https://www.who.int/emergencies/disease-outbreak-news/item/2024-DON512
[18] https://www.cdc.gov/flu/avianflu/what-cdc-doing-h5n1.htm
[19] https://www.iata.org/contentassets/028b3d4ec3924cb393155c84784161ac/guidance-for-vaccine-and-pharmaceutical-logistics-and-distribution---global-collaboration_onepager_general.pdf
[20] https://www.cdc.gov/flu/avianflu/avian-flu-summary.htm
------------------------------
Thank you for reading! If you like what we researched for you and presented in this blog post, and would like to read more blog posts like this, please consider signing up for email updates by